Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
<h4>Background</h4>The stem cell factor receptor, KIT, is a target for the treatment of cancer, mastocytosis, and inflammatory diseases. Here, we characterise the in vitro and in vivo profiles of masitinib (AB1010), a novel phenylaminothiazole-type tyrosine kinase inhibitor that targets...
Guardado en:
Autores principales: | Patrice Dubreuil, Sébastien Letard, Marco Ciufolini, Laurent Gros, Martine Humbert, Nathalie Castéran, Laurence Borge, Bérengère Hajem, Anne Lermet, Wolfgang Sippl, Edwige Voisset, Michel Arock, Christian Auclair, Phillip S Leventhal, Colin D Mansfield, Alain Moussy, Olivier Hermine |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/63537d296c7e47bf89a26c076d6d1533 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.
por: Daniela Silva Moura, et al.
Publicado: (2011) -
Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology
por: Kahina Hammam, et al.
Publicado: (2017) -
Medical approach to the treatment of feline injection site sarcoma with masitinib: a case report
por: Ledoux JM, et al.
Publicado: (2014) -
Acta N°1010
por: Banco Central de Chile
Publicado: (2021) -
Synthesis and structure of 2,8-dimethyl-10,10-dichlorophenoxatellurine
por: Mostaghimi Farzin, et al.
Publicado: (2021)